Abstract
The scope of 6,8-dioxa-3-aza-bicyclo(3.2.1)octane derivatives as morpholine replacing groups in bioactive compounds was investigated. Four derivatives were synthesized and subjected to the routinary screening strategy, as part of a project directed to obtain new tachykinin NK2 antagonists. The obtained results encourage further study on the heterobicycle 6,8-dioxa-3-aza-bicyclo(3.2.1)octane as morpholine surrogate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
